Subcellular localization of Mdm2 expression and prognosis of breast cancer

Hyung Seok Park, Ji Min Park, Seho Park, Junghoon Cho, Seung Il Kim, Byeongwoo Park

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Methods: p53 and Mdm2 expressions were determined by immunohistochemistry of tissue microarrays of 865 breast cancer patients who underwent surgery. Clinicopathological characteristics and survival data were analyzed. Mdm2 expression was categorized into four groups: negative, cytoplasm positive, nucleus positive, and concurrent nuclear and cytoplasm positive (N+&C+).

Background: Mouse double minute 2 (Mdm2) is a negative regulator of the tumor suppressor p53. The p53–Mdm2 pathway may play a role in cancer development and prognosis, although the role of p53–Mdm2 in breast cancer remains unclear.

Results: Negative, cytoplasm-positive, nucleus-positive, and N+&C+ expressions of Mdm2 were observed in 59.2, 10.9, 27.8, and 2.1 % of patients, respectively. The N+&C+ group was associated with larger tumor size, higher grade, negativity for estrogen and progesterone receptors, HER2 positivity, high Ki-67 index, p53 positivity, and triple negative breast cancer. p53-positive tumors showed poorer overall survival than p53-negative tumors. The nucleus-positive and N+&C+ groups showed poorer disease-free survival than the negative and cytoplasm-positive groups. In multivariate analysis, nuclear Mdm2 expression including the N+&C+ group was significantly related to poor prognosis.

Conclusions: Concurrent nuclear and cytoplasmic Mdm2 expression was an independent prognostic factor in patients with breast cancer. Subcellular localization of Mdm2 expression should be considered in the evaluation of Mdm2 in breast cancer.

Original languageEnglish
Pages (from-to)842-851
Number of pages10
JournalInternational Journal of Clinical Oncology
Volume19
Issue number5
DOIs
Publication statusPublished - 2014 Oct 16

Fingerprint

Breast Neoplasms
Cytoplasm
Neoplasms
Triple Negative Breast Neoplasms
Survival
Progesterone Receptors
Estrogen Receptors
Disease-Free Survival
Multivariate Analysis
Immunohistochemistry

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hematology
  • Oncology

Cite this

Park, Hyung Seok ; Park, Ji Min ; Park, Seho ; Cho, Junghoon ; Kim, Seung Il ; Park, Byeongwoo. / Subcellular localization of Mdm2 expression and prognosis of breast cancer. In: International Journal of Clinical Oncology. 2014 ; Vol. 19, No. 5. pp. 842-851.
@article{0cb91e81e75a4539bd219685a941608c,
title = "Subcellular localization of Mdm2 expression and prognosis of breast cancer",
abstract = "Methods: p53 and Mdm2 expressions were determined by immunohistochemistry of tissue microarrays of 865 breast cancer patients who underwent surgery. Clinicopathological characteristics and survival data were analyzed. Mdm2 expression was categorized into four groups: negative, cytoplasm positive, nucleus positive, and concurrent nuclear and cytoplasm positive (N+&C+).Background: Mouse double minute 2 (Mdm2) is a negative regulator of the tumor suppressor p53. The p53–Mdm2 pathway may play a role in cancer development and prognosis, although the role of p53–Mdm2 in breast cancer remains unclear.Results: Negative, cytoplasm-positive, nucleus-positive, and N+&C+ expressions of Mdm2 were observed in 59.2, 10.9, 27.8, and 2.1 {\%} of patients, respectively. The N+&C+ group was associated with larger tumor size, higher grade, negativity for estrogen and progesterone receptors, HER2 positivity, high Ki-67 index, p53 positivity, and triple negative breast cancer. p53-positive tumors showed poorer overall survival than p53-negative tumors. The nucleus-positive and N+&C+ groups showed poorer disease-free survival than the negative and cytoplasm-positive groups. In multivariate analysis, nuclear Mdm2 expression including the N+&C+ group was significantly related to poor prognosis.Conclusions: Concurrent nuclear and cytoplasmic Mdm2 expression was an independent prognostic factor in patients with breast cancer. Subcellular localization of Mdm2 expression should be considered in the evaluation of Mdm2 in breast cancer.",
author = "Park, {Hyung Seok} and Park, {Ji Min} and Seho Park and Junghoon Cho and Kim, {Seung Il} and Byeongwoo Park",
year = "2014",
month = "10",
day = "16",
doi = "10.1007/s10147-013-0639-1",
language = "English",
volume = "19",
pages = "842--851",
journal = "International Journal of Clinical Oncology",
issn = "1341-9625",
publisher = "Springer Japan",
number = "5",

}

Subcellular localization of Mdm2 expression and prognosis of breast cancer. / Park, Hyung Seok; Park, Ji Min; Park, Seho; Cho, Junghoon; Kim, Seung Il; Park, Byeongwoo.

In: International Journal of Clinical Oncology, Vol. 19, No. 5, 16.10.2014, p. 842-851.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Subcellular localization of Mdm2 expression and prognosis of breast cancer

AU - Park, Hyung Seok

AU - Park, Ji Min

AU - Park, Seho

AU - Cho, Junghoon

AU - Kim, Seung Il

AU - Park, Byeongwoo

PY - 2014/10/16

Y1 - 2014/10/16

N2 - Methods: p53 and Mdm2 expressions were determined by immunohistochemistry of tissue microarrays of 865 breast cancer patients who underwent surgery. Clinicopathological characteristics and survival data were analyzed. Mdm2 expression was categorized into four groups: negative, cytoplasm positive, nucleus positive, and concurrent nuclear and cytoplasm positive (N+&C+).Background: Mouse double minute 2 (Mdm2) is a negative regulator of the tumor suppressor p53. The p53–Mdm2 pathway may play a role in cancer development and prognosis, although the role of p53–Mdm2 in breast cancer remains unclear.Results: Negative, cytoplasm-positive, nucleus-positive, and N+&C+ expressions of Mdm2 were observed in 59.2, 10.9, 27.8, and 2.1 % of patients, respectively. The N+&C+ group was associated with larger tumor size, higher grade, negativity for estrogen and progesterone receptors, HER2 positivity, high Ki-67 index, p53 positivity, and triple negative breast cancer. p53-positive tumors showed poorer overall survival than p53-negative tumors. The nucleus-positive and N+&C+ groups showed poorer disease-free survival than the negative and cytoplasm-positive groups. In multivariate analysis, nuclear Mdm2 expression including the N+&C+ group was significantly related to poor prognosis.Conclusions: Concurrent nuclear and cytoplasmic Mdm2 expression was an independent prognostic factor in patients with breast cancer. Subcellular localization of Mdm2 expression should be considered in the evaluation of Mdm2 in breast cancer.

AB - Methods: p53 and Mdm2 expressions were determined by immunohistochemistry of tissue microarrays of 865 breast cancer patients who underwent surgery. Clinicopathological characteristics and survival data were analyzed. Mdm2 expression was categorized into four groups: negative, cytoplasm positive, nucleus positive, and concurrent nuclear and cytoplasm positive (N+&C+).Background: Mouse double minute 2 (Mdm2) is a negative regulator of the tumor suppressor p53. The p53–Mdm2 pathway may play a role in cancer development and prognosis, although the role of p53–Mdm2 in breast cancer remains unclear.Results: Negative, cytoplasm-positive, nucleus-positive, and N+&C+ expressions of Mdm2 were observed in 59.2, 10.9, 27.8, and 2.1 % of patients, respectively. The N+&C+ group was associated with larger tumor size, higher grade, negativity for estrogen and progesterone receptors, HER2 positivity, high Ki-67 index, p53 positivity, and triple negative breast cancer. p53-positive tumors showed poorer overall survival than p53-negative tumors. The nucleus-positive and N+&C+ groups showed poorer disease-free survival than the negative and cytoplasm-positive groups. In multivariate analysis, nuclear Mdm2 expression including the N+&C+ group was significantly related to poor prognosis.Conclusions: Concurrent nuclear and cytoplasmic Mdm2 expression was an independent prognostic factor in patients with breast cancer. Subcellular localization of Mdm2 expression should be considered in the evaluation of Mdm2 in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84919343110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919343110&partnerID=8YFLogxK

U2 - 10.1007/s10147-013-0639-1

DO - 10.1007/s10147-013-0639-1

M3 - Article

C2 - 24292333

AN - SCOPUS:84919343110

VL - 19

SP - 842

EP - 851

JO - International Journal of Clinical Oncology

JF - International Journal of Clinical Oncology

SN - 1341-9625

IS - 5

ER -